We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
INTEGRA BIOSCIENCES AG

Roche Diagnostics

Develops, manufactures, and markets a wide range of in vitro diagnostic systems, instruments, reagents, and tests read more Featured Products: More products

Download Mobile App





Roche Showcases Solutions for Laboratories of the Future

By LabMedica International staff writers
Posted on 30 Jul 2024

Roche (Basel, Switzerland) is showcasing a laboratory of the future exhibit at the 2024 Association for Diagnostics & Laboratory Medicine (ADLM) Scientific Meeting and Clinical Lab Expo. More...

Attendees can experience how Roche's growing portfolio of integrated systems and data solutions optimizes resources and simplifies and streamlines operations while driving better health outcomes.

Focusing on key attributes of science-based leadership, operational simplicity, and patient-centric partnership, Roche is featuring its newest innovations in-booth at ADLM. These include the future cobas Mass Spec solution designed to be a total end-to-end solution for clinical mass spectrometry testing with the goal of seamless integration into the routine laboratory. Roche is also highlighting the new CCM Vertical, a flexible modular system that uses lab space effectively and seamlessly integrates into the existing cobas connection modules. Also featuring at ADLM 2024 is the cobas liat system which brings gold-standard PCR technology to the point of care, providing results within 20 minutes across a growing menu of assays.

The cobas pure integrated solutions which combine clinical chemistry, immunoassay and Ion-Selective Electrode (ISE) diagnostic testing on a single platform for low- to mid-volume testing needs are also being highlighted at the meeting. Additionally, Roche is featuring the cobas eplex system, a rapid syndromic molecular diagnostic solution that has been updated with new features across all aspects of the workflow process, alongside the cobas 5800 is a compact, fully automated molecular PCR-testing solution with a comprehensive menu of assays. Visitors to the Roche booth can also experience the cobas LightCycler PRO qPCR system which is designed to deliver accuracy and flexibility to research and clinical diagnostic laboratories with an improved user experience.

At ADLM 2024, Roche is also presenting its full array of navify digital solutions, which securely integrate data across care settings, connecting the healthcare community and accelerating access to innovation and insights. Roche is also presenting eight Roche Idea Lab segments in its booth, where experts will discuss topics such as mass spectrometry, digital solutions, respiratory testing, and the use of high-medical-value assays when treating Alzheimer's and heart failure. Scientific industry workshops include "Laboratorians' Perspectives on Evaluation and Implementation of Alzheimer's CSF Assays" and "Making a Subjective Sepsis Diagnosis More Objective: The Role of AI-based Sepsis Medical Algorithms in Empowering Healthcare Decisions."

"Laboratorians strive to deliver trusted, timely test results to patients with greater effectiveness and efficiency. Our latest generation of cobas solutions are proven to deliver seamless integration of systems and data to support these efforts," said Brad Moore, president and CEO of Roche Diagnostics North America. "We are excited to share these next-generation solutions, which are the building blocks for future laboratories, and are eager to partner with our customers so that they can both do more with less and deliver the best possible outcomes for patients."


Platinum Member
Automated Coagulation Analyzer
Hemolumi H6
Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
POC Immunoassay Analyzer
Procise DX
All-in-One Molecular System
AIO M160
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: A large, international study led by City of Hope found that the new, investigational liquid biopsy, called PANXEON, was highly sensitive in detecting stage 1 and 2 pancreatic cancer and had a low rate of false positives. The test was also able to identify high-grade dysplasia, a precancerous condition of the pancreas, potentially enabling intervention before cancer develops. (Photo courtesy of City of Hope)

Multi-Biomarker Blood Test Shows Promise for Early Pancreatic Cancer Detection

Pancreatic cancer has the lowest survival rates of any cancer, with only 14% of patients alive five years after diagnosis. The disease is typically discovered after it has spread, and an estimated 90%... Read more

Microbiology

view channel
Image: Graphical Abstract (Jose A. Céspedes, Maria I. Montañez, Isabel M. Jiménez, et al. Magnetic nanoparticles enable clinically relevant in vitro diagnosis of beta-lactam allergy. Materials Today Bio (2026). DOI: 10.1016/j.mtbio.2026.103356)

Magnetic Nanoparticles Enable More Sensitive Beta-Lactam Allergy Testing

Penicillin allergy labels are common in clinical practice, yet many are incorrect and can lead to suboptimal antibiotic choices. Although 8%–25% of people report a penicillin allergy, only 1%–10% are truly... Read more

Technology

view channel
Image: Graphical Abstract (Wenjie Zhang, Zeyu Luo, Kaijie Liu, et al. Science Bulletin, 2026. doi:10.1016/j.scib.2026.09.016)

Multimodal AI Framework Aims to Guide Cancer Immunotherapy Decisions

Cancer immunotherapy has reshaped oncology, but heterogeneous responses and immune-related toxicities continue to complicate routine decision-making. Standard biomarkers, including programmed death-ligand... Read more

Industry

view channel
Image: The acquisition adds Convergent Genomics’ UroAmp platform and proprietary urinary tumor DNA technology to Veracyte’s portfolio (Photo courtesy of Convergent Genomics)

Veracyte Acquisition Expands Urine-Based Bladder Cancer Monitoring Capabilities

Veracyte, Inc. has acquired Convergent Genomics, expanding its urology diagnostics offerings with the company’s UroAmp platform and proprietary urinary tumor DNA (utDNA) technology. UroAmp has been clinically... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.